These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20655383)

  • 1. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells.
    Yoon SY; Park JS; Choi JE; Choi JM; Lee WJ; Kim SW; Kim DH
    Neurobiol Dis; 2010 Nov; 40(2):449-55. PubMed ID: 20655383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons.
    Cho DH; Lee EJ; Kwon KJ; Shin CY; Song KH; Park JH; Jo I; Han SH
    J Neurochem; 2013 Sep; 126(5):685-95. PubMed ID: 23581463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.
    Kim DH; Huh JW; Jang M; Suh JH; Kim TW; Park JS; Yoon SY
    Neurobiol Dis; 2012 Apr; 46(1):52-8. PubMed ID: 22245388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway.
    Tokutake T; Kasuga K; Yajima R; Sekine Y; Tezuka T; Nishizawa M; Ikeuchi T
    J Biol Chem; 2012 Oct; 287(42):35222-35233. PubMed ID: 22910909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation.
    Jämsä A; Hasslund K; Cowburn RF; Bäckström A; Vasänge M
    Biochem Biophys Res Commun; 2004 Jul; 319(3):993-1000. PubMed ID: 15184080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seipin deletion in mice enhances phosphorylation and aggregation of tau protein through reduced neuronal PPARγ and insulin resistance.
    Chang H; Di T; Wang Y; Zeng X; Li G; Wan Q; Yu W; Chen L
    Neurobiol Dis; 2019 Jul; 127():350-361. PubMed ID: 30910747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarsasapogenin attenuates Alzheimer-like encephalopathy in diabetes.
    Zhang YM; Zheng T; Huang TT; Gu PP; Gou LS; Ma TF; Liu YW
    Phytomedicine; 2021 Oct; 91():153686. PubMed ID: 34333330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes.
    Xu W; Yang Y; Yuan G; Zhu W; Ma D; Hu S
    J Investig Med; 2015 Feb; 63(2):267-72. PubMed ID: 25479064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of JNK phosphorylation as a mechanism for rosiglitazone in neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase.
    Okami N; Narasimhan P; Yoshioka H; Sakata H; Kim GS; Jung JE; Maier CM; Chan PH
    J Cereb Blood Flow Metab; 2013 Jan; 33(1):106-14. PubMed ID: 23032483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent increases in tau phosphorylation in the brains of type 2 diabetic rats correlate with a reduced expression of p62.
    Jung HJ; Kim YJ; Eggert S; Chung KC; Choi KS; Park SA
    Exp Neurol; 2013 Oct; 248():441-50. PubMed ID: 23906983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exendin-4 reduces tau hyperphosphorylation in type 2 diabetic rats via increasing brain insulin level.
    Yang Y; Ma D; Xu W; Chen F; Du T; Yue W; Shao S; Yuan G
    Mol Cell Neurosci; 2016 Jan; 70():68-75. PubMed ID: 26640240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of stereotaxically injected IgG from db/db mice in the phosphorylation of the microtubule-associated protein tau in hippocampus.
    Shuai H; Zhang J; Zhang J; Xie J; Zhang M; Ma J; Zhang L; Wang X
    Brain Res; 2012 Nov; 1486():14-26. PubMed ID: 23036273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troglitazone, a peroxisome proliferator-activated receptor-gamma agonist, decreases tau phosphorylation in CHOtau4R cells.
    d'Abramo C; Ricciarelli R; Pronzato MA; Davies P
    J Neurochem; 2006 Aug; 98(4):1068-77. PubMed ID: 16787414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes.
    Yang Y; Ma D; Wang Y; Jiang T; Hu S; Zhang M; Yu X; Gong CX
    J Alzheimers Dis; 2013; 33(2):329-38. PubMed ID: 22936005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo.
    Bitner RS; Nikkel AL; Markosyan S; Otte S; Puttfarcken P; Gopalakrishnan M
    Brain Res; 2009 Apr; 1265():65-74. PubMed ID: 19230830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro.
    Ma QL; Lim GP; Harris-White ME; Yang F; Ambegaokar SS; Ubeda OJ; Glabe CG; Teter B; Frautschy SA; Cole GM
    J Neurosci Res; 2006 Feb; 83(3):374-84. PubMed ID: 16385556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation.
    Sahara N; Murayama M; Lee B; Park JM; Lagalwar S; Binder LI; Takashima A
    Eur J Neurosci; 2008 Jun; 27(11):2897-906. PubMed ID: 18540881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
    Khandoudi N; Delerive P; Berrebi-Bertrand I; Buckingham RE; Staels B; Bril A
    Diabetes; 2002 May; 51(5):1507-14. PubMed ID: 11978649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.